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Preface 
Ian Phillks and Lowell Young 
p-Lactamases were among the first antibiotic resistance 
mechanisms to be recognized in both Gram-negative 
and Gram-positive bacteria, almost at the same time as 
the p-lactams themselves. While Staphylococcus aureus 
became and remained a major problem, the increase in 
the prevalence of @-lactamase production caused 
concern, but the staphylococci and other Gram- 
positive pathogens largely turned to other mechanisms 
to achieve hrther resistance to p-lactam antibiotics, and 
it is these mechanisms alongside resistance to other 
drug classes that currently preoccupy us. 
The Gram-negative organisms appeared to follow 
suit, particularly with plasmid-mediated p-lactamases. 
Indeed, the original TEM enzyme has become one of 
the most widely disseminated resistance mechanisms. 
However, two events have changed the perspective. 
The first was the emergence of chromosomally- 
mediated p-lactamases, more or less silently present in 
most Gram-negative bacteria, as a clinical problem in 
such organisms as Enterobacter, Citrobacter and 
Serratia, particularly in hospitals, and there in special 
units. The second was the sudden plethora of mutant 
TEMs (and other plasmid-mediated enzymes), which 
severely affected the usefulness of a range of p-lactams 
designed to combat the original TEM and TEM-like 
enzymes. It is in this context that the carbapenem 
antibiotics have, so far, very largely held their own, the 
Achilles' heel appearing to be the currently rare 
metalloenzymes found in Stenotrophomonas maltophilia 
and Bacteroides fragilis and, more recently, in plasmid- 
mediated form in Pseudomonas aeruginosa and Serratia 
SPP. 
To date, apart from S. rnaltophilia, the threat to 
carbapenems sc'ems far distant, but the lesson from the 
past is that the intensive use of carbapenems is likely 
to be a selective force. The past also tells us that the 
catastrophe of P-lactamase-mediated resistance to all 
p-lactarn antibiotics that would probably ensue may 
disseminate rapidly, may not arise at all or may be long- 
delayed. In the meantime, it seems at least prudent to 
use carbapenems when they can be shown to be 
effective and conserve them when other agents with 
lesser potential for the selection of damaging resistance 
can be used. 
This supplement documents the current status 
of the p-lactamases and suggests clinical contents 
in which carbapenems, and particularly meropenern, 
might be most useful. It is based on a symposium 
held as part of the 1996 International Conference of 
Infectious Diseases held in Hong Kong. We are grateful 
to Zeneca Pharmaceuticals for making the Symposium 
and this supplement possible. 
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